The invention provides tertiary structures) of cyclic nonapeptide ICAM-1 inhibitors and methods of using the tertiary structures tp identify additional ICAM-1 inhibitors, particularly non-peptide modulators. The invention also provides methods of treating ICAM1/LFA-1 mediated diseases comprising administ4ring a non-peptide ICAM-1 modulator of the invention to a patient in need thereof.